Microbiology and Treatment Outcome of Acute Exacerbation of Bronchiectasis in Hong Kong

NCT05112055 | Recruiting

• 1 other identifier: Pro_AEB_2021
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Bronchiectasis is a common disease worldwide with a high burden on healthcare resources. In Hong Kong (HK), local microbiological and clinical data regarding acute exacerbation of bronchiectasis (AEB) is lacking, in particular the frequency of pseudomonas aeruginosa (PA) in AEB is yet to be elucidated. A better understanding of the microbiology of AEB will provide evidence for judicious use of appropriate antibiotics in patients hospitalized for AEB to facilitate treatment and discharge. This study aims to

1. 1.elucidate the microbiology of AEB using both traditional culture and newer molecular multiplex methods,
2. 2.identify factors associated with PA infection, and
3. 3.describe the management and treatment outcome of AEB in HK

Conditions

Bronchiectasis

Outcome Measures

Primary Outcomes (2)

• Microbiology

  Frequency of pseudomonas aeruginosa (PA) and non-PA infection

  1 month

• Risk factors for PA infection

  Risk factors for PA infection

  1 month

Secondary Outcomes (4)

• Antibiotics use

  1 month

• Length of stay

  1 month

• Recurrent exacerbation

  12 months

• Mortality

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a prospective observational study of patients who are admitted to the participating hospital with acute exacerbations of bronchiectasis.

You may qualify if:

• Patients admitted to participating hospital with a clinical diagnosis of acute exacerbation of bronchiectasis (AEB), defined as a change in bronchiectasis treatment associated with deterioration in three or more of the following key symptoms for at least 48 hours: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; or haemoptysis.
• Patients with an established diagnosis of bronchiectasis, defined as the presence of cough, shortness of breath, chronic sputum production, recurrent respiratory infection, or a combination thereof with CT thorax scan confirmation of the presence of bronchiectasis indicated by a bronchoarterial ratio of \> 1, lack of tapering, airway visibility within 1 cm of the pleural surface, or a combination thereof.

You may not qualify if:

• Patients unable to provide informed consent
• Age \< 18 years
• Pregnancy
• Bronchiectasis due to known cystic fibrosis
• Bronchiectasis is not the main or co-dominant respiratory disease
• Traction bronchiectasis due to interstitial lung disease
• Prior lung transplantation for bronchiectasis

Sponsors & Collaborators

• Pamela Youde Nethersole Eastern Hospital: lead

Study Sites (1)

Charles Wong

Hong Kong, Other, Hong Kong

RECRUITING

MeSH Terms

Conditions

Bronchiectasis

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases

Study Officials

• Charles Wong

  Pamela Youde Nethersole Eastern Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Charles Wong

CONTACT

25956111; wc679@ha.org.hk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Specialist

Study Record Dates

• First Submitted: October 8, 2021
• First Posted: November 8, 2021
• Study Start: December 2, 2021
• Primary Completion: February 28, 2025
• Study Completion: December 1, 2025
• Last Updated: April 3, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)